ABSTRACT
The risks and benefits of spinal anaesthesia must be assessed in patients with coagulation disorders. A woman in her 20s with congenital factor VII (FVII) deficiency (31%) was admitted at 38 weeks for caesarean delivery. A rotational thromboelastometry (ROTEM) analysis showed normal coagulation and spinal anaesthesia was performed safely. A repeated ROTEM analysis after haemostasis and uterine closure showed normal coagulation without fibrinolysis. No prophylactic FVII was administered, resulting in a cost savings of US$12 884. FVII level did not predict bleeding or fibrinolysis and FVII and tranexamic acid were not indicated.
Subject(s)
Anesthesia, Obstetrical , Anesthesia, Spinal , Cesarean Section , Factor VII Deficiency , Thrombelastography , Humans , Female , Anesthesia, Spinal/methods , Thrombelastography/methods , Pregnancy , Factor VII Deficiency/complications , Factor VII Deficiency/blood , Anesthesia, Obstetrical/methods , Adult , Pregnancy Complications, Hematologic/bloodABSTRACT
OBJECTIVE: To investigate a family with factor VII (FVII) deficiency from Argentina. PATIENTS AND METHODS: The proposita is a 14-year-old girl who presented with a mild to moderate bleeding tendency. Menorrhagia is controlled with periodical administration of small doses of recombinant FVII concentrate. The mother of the proposita has a similar bleeding tendency. RESULTS: FVII activity in both patients was 20% of normal; FVII antigen was 35% of normal. Molecular biology investigation revealed that the proposita was compound heterozygote between Thr384Met and Arg413Gln. The mother had the same mutations. This was due to the fact that the father of the proposita and her maternal grandfather both carried, in spite of no relation, the same mutation, namely Arg413Gln. CONCLUSIONS: The identical defect which presented in the propositaand her mother could be explained by the genetic analysis of the father and maternal grandfather of the proposita who happened to have the same mutation (Arg413Gln).
Subject(s)
Amino Acid Substitution , Factor VII Deficiency/diagnosis , Factor VII Deficiency/genetics , Factor VII/genetics , Heterozygote , Mutation , Phenotype , Adolescent , Adult , Argentina , Blood Coagulation Tests , DNA Mutational Analysis , Factor VII Deficiency/blood , Factor VIIa/administration & dosage , Female , Genetic Association Studies , Humans , PedigreeABSTRACT
INTRODUCTION: Inherited factor VII deficiency is the most common autosomal recessive inherited bleeding disorder, with an estimated incidence of one per 500 000 cases in the general population. Bleeding manifestations correlate poorly with circulating FVII levels. During pregnancy, increases in FVII levels can occur in women with mild-moderate FVII deficiencies but not in those with severe deficiency. AIM: We present five pregnant patients with FVII deficiency and describe the management during their pregnancies and peripartum periods. METHODS: Retrospective analysis of six pregnancies in five women with FVII deficiency followed during pregnancy and delivery at an academic medical centre between January 2013 and December 2019. RESULTS: Of the five patients, two had severe, one with moderate and two with mild FVII deficiency. Early postpartum haemorrhage (PPH) occurred in two patients. One of the two severe FVII-deficient patients had PPH with a laceration at delivery despite replacement therapy with recombinant factor VII. The other PPH occurred in a patient with mild FVII deficiency who delivered twins by caesarean section under general anaesthesia. Neuraxial anaesthesia was utilized in only one woman with mild deficiency whose FVII level normalized at the end of the pregnancy. CONCLUSIONS: Management of delivery for women with FVII deficiency should be addressed on a case-by-case basis at centres with expertise in rare bleeding disorders, maternal foetal medicine and obstetric anaesthesiology. These management discussions should factor the patient's bleeding history, third trimester PT, FVII level, multiple gestation and mode of delivery.
Subject(s)
Factor VII Deficiency/congenital , Factor VII Deficiency/drug therapy , Factor VII/analysis , Hemorrhage/prevention & control , Patient Care Management/methods , Postpartum Hemorrhage/etiology , Adult , Blood Coagulation Disorders, Inherited/epidemiology , Blood Coagulation Disorders, Inherited/ethnology , Cesarean Section/methods , Cesarean Section/statistics & numerical data , Factor VII/therapeutic use , Factor VII Deficiency/blood , Factor VII Deficiency/complications , Female , Hemorrhage/etiology , Humans , Incidence , Peripartum Period , Postpartum Hemorrhage/epidemiology , Pregnancy , Pregnancy Complications, Hematologic , Retrospective Studies , Severity of Illness Index , Treatment OutcomeABSTRACT
Factor VII deficiency is the most common of the rare coagulation deficiencies. A hemorrhagic syndrome may occur in patients with FVII deficiency below 20%, although no correlation exist between the plasma FVII activity level (FVII:C) and the bleeding risk. Therefore, the management of surgery in patients with FVII deficiency remains challenging. Laboratory monitoring of FVII:C level may be helpful but should be interpreted with caution, because the dosage of FVII:C level may vary depending on the origin of the thromboplastin used. Herein, we report the case of the management of a woman who had been fortuitously diagnosed during pregnancy with FVII deficiency due to FVII variant Padua, which have induced discrepant results between two different laboratories.
Subject(s)
Factor VII Deficiency/diagnosis , Factor VII Deficiency/genetics , Factor VII/genetics , Factor VII/metabolism , Pregnancy Complications, Hematologic/diagnosis , Thromboplastin/metabolism , Adult , Amino Acid Substitution , Blood Coagulation/genetics , Blood Coagulation Tests , Factor VII/analysis , Factor VII Deficiency/blood , Female , Humans , Incidental Findings , Infant, Newborn , Mutation, Missense , Pregnancy , Pregnancy Complications, Hematologic/genetics , Thromboplastin/analysisABSTRACT
Objectives: Recombinant fusion protein linking activated factor VIIa to human albumin (rVIIa-FP) is a therapeutic option designed to prevent and treat bleeding events in patients with congenital FVII deficiency with reduced infusion frequency compared to current FVII treatments. This study characterized the pharmacokinetics (PK) and pharmacodynamics (PD) of rVIIa-FP.Methods: A phase I multicenter, randomized, open-label, parallel-arm, single-dose study (NCT02470871) was conducted in nine patients with severe congenital FVII deficiency. Patients received their routine FVII product (30â IU/kg plasma-derived FVII [pdFVII] or 25â µg/kg recombinant activated FVII (rFVIIa) [eptacog alfa]), and were then randomly assigned to receive 100 or 300â µg/kg of rVIIa-FP. Blood samples for PK and PD assessments were drawn up to 48â hr after administration. FVIIa activity was determined using a one-stage clotting assay. PD parameters were derived from thrombin generation testing, using the Nijmegen hemostasis assay.Results: rVIIa-FP showed improved PK compared to rFVIIa, with 2- to 3-fold longer t1/2 and 4- to 8-fold lower clearance. Analysis of PD data showed a sustained suppression of lag time below 4.5â min (upper limit of healthy people) for rVIIa-FP compared to rFVIIa. AUEC and ECmax were similar across the two dose groups of rVIIa-FP and rFVIIa.Discussion: rVIIa-FP was well tolerated in patients with congenital FVII deficiency, showed a longer half-life and lower clearance compared to rFVIIa, and lag time remaining within healthy ranges for ≥8â hr.Conclusion: These results warrant further investigation into the efficacy of rVIIa-FP to control and prevent bleeding in patients with FVII deficiency.
Subject(s)
Factor VII Deficiency/drug therapy , Factor VIIa/therapeutic use , Adult , Blood Coagulation/drug effects , Factor VII Deficiency/blood , Factor VIIa/adverse effects , Factor VIIa/pharmacology , Female , Humans , Male , Middle Aged , Recombinant Fusion Proteins/adverse effects , Recombinant Fusion Proteins/blood , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/therapeutic use , Recombinant Proteins/adverse effects , Recombinant Proteins/blood , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use , Serum Albumin, Human/adverse effects , Serum Albumin, Human/analysis , Serum Albumin, Human/pharmacology , Serum Albumin, Human/therapeutic use , Treatment Outcome , Young AdultABSTRACT
INTRODUCTION: Inherited factor VII (FVII) deficiency is the most common of the rare bleeding disorders and shows a heterogenous distribution of bleeding phenotypes independent of factor activity level. The bleeding score (BS) evaluates the phenotype of patients with rare bleeding disorders. Thromboelastography (TEG) and thrombin generation assays (TGAs) are 2 methods to evaluate global hemostasis, and controversially both tests are useful for identifying different bleeding tendency phenotypes. The purpose of this study was to investigate the use of the BS and global assays (TEG and TGAs) to predict the bleeding phenotype of inherited FVII deficiency. MATERIALS AND METHODS: A total of 27 patients with FVII deficiency were evaluated with the BS and global hemostasis assays. RESULTS: The BS was compatible with disease severity according to the FVII activity level (P<0.05) but the BS and bleeding grade of patients did not show a statistically significant correlation with factor activity level (P>0.05). No significant correlation was observed between the factor activity level and any TEG parameter (P>0.05). The factor activity level was negatively correlated with the lag time of the TGA on the contrary positively correlated with the peak thrombin time of the TGA (P<0.05). CONCLUSIONS: The global assays do not successfully predict the bleeding phenotype. The BS is a more suitable tool than conventional and global assays for predicting the bleeding phenotype.
Subject(s)
Blood Coagulation Disorders, Inherited/diagnosis , Blood Coagulation Tests/methods , Factor VII Deficiency/diagnosis , Severity of Illness Index , Thrombelastography/methods , Thrombin/analysis , Adolescent , Blood Coagulation Disorders, Inherited/blood , Blood Coagulation Disorders, Inherited/metabolism , Case-Control Studies , Child , Child, Preschool , Factor VII Deficiency/blood , Factor VII Deficiency/metabolism , Female , Follow-Up Studies , Hemostasis , Humans , Male , Phenotype , Predictive Value of TestsABSTRACT
BACKGROUND: To identify potential mutations and analyze the phenotype in an inherited factor VII (FVII) deficiency pedigree. METHODS: Prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, FVII activity (FVII:C), FVII antigen (FVII:Ag) and other coagulant parameters of the proband and family members were measured. Calibrated automated thrombin generation measurements were used to detect coagulation status. All the exons, exonintron boundaries and 5', 3' untranslated sequences of the F7 gene in the proband and other family members were amplified by polymerase chain reaction (PCR). The PCR products were screened by direct sequencing. The detected mutations were confirmed by sequencing the other strand and analyzed by PIC software. RESULTS: The PT in the proband was prolonged and further study showed that the FVII:C and FVII:Ag were below the normal range, 3% and 38%, respectively. Double heterozygous mutations in the proband were identified: an A to G mutation at position 11,459 in exon 8, resulting in a p.Lys341Glu substitution, and a 2bp deletion (nt 27 del CT) mutation in exon 1a, leading to a frameshift and the creation of a premature stop codon. Both endogenous thrombin potential (ETP) and peak height in the proband were declined. Her father, brother, daughter, son, and niece were heterozygous for the nt 27 del CT mutation, while her mother, little brother, little niece, and little nephew were heterozygous for the Lys341Glu mutation, and their ETP and peak height obtained more than half normal ETP and peak height, respectively. Model analysis indicated that the Lys341Glu mutation will interrupt the electrovalent bond between 341Lys and 289Asp. CONCLUSIONS: Compound heterozygous mutations (p.Lys341Glu and nt27 del CT) which were responsible for the bleeding tendency were found in a pedigree of inherited FVII deficiency. The Lys341Glu mutation is firstly reported and nt27 del CT may be one of the mutational spots in Chinese population.
Subject(s)
Antigens/genetics , Factor VII Deficiency/genetics , Factor VII/genetics , Mutation , Adolescent , Adult , Aged , Antigens/blood , Asian People/genetics , Child , China , Factor VII Deficiency/blood , Factor VII Deficiency/ethnology , Female , Genotype , Heterozygote , Humans , Male , Middle Aged , Partial Thromboplastin Time , Pedigree , Phenotype , Prothrombin Time , Young AdultABSTRACT
Acquired isolated factor VII deficiency is a rare bleeding disorder and has been reported in 31 cases. This is in contrast to congenital factor VII deficiency, which while also infrequent is the most common rare congenital bleeding disorder. Acquired isolated factor VII deficiency has been described primarily in patients with solid malignancies, sepsis, and in the presence of anti-factor VII autoantibodies. We report a case of acute myelogenous leukemia with an associated trisomy 8 cytogenetic abnormality presenting with factor VII deficiency. The factor VII deficiency cleared after induction chemotherapy and with the disappearance of the cytogenetic and molecular abnormalities. We discuss a possible link between trisomy 8 and vitamin K metabolism, which might result in acquired factor VII deficiency in acute myelogenous leukemia.
Subject(s)
Factor VII Deficiency/etiology , Leukemia, Myeloid, Acute/complications , Trisomy/pathology , Adult , Antineoplastic Agents/therapeutic use , Chromosomes, Human, Pair 8 , Factor VII Deficiency/blood , Factor VII Deficiency/genetics , Female , Humans , Leukemia, Myeloid, Acute/blood , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/geneticsSubject(s)
Compartment Syndromes/diagnosis , Factor VII Deficiency/complications , Orthopedic Procedures/methods , Orthopedics/statistics & numerical data , Osteomyelitis/complications , Thigh/pathology , Adolescent , Aftercare , Aged, 80 and over , Compartment Syndromes/surgery , Factor VII/administration & dosage , Factor VII Deficiency/blood , Fasciotomy/methods , Female , Hematoma/diagnostic imaging , Humans , Male , Middle Aged , Osteomyelitis/diagnostic imaging , Pain/etiology , Thigh/surgery , Thrombosis/etiology , Thrombosis/therapy , Treatment Outcome , Vena Cava, Inferior/diagnostic imaging , Vena Cava, Inferior/pathology , Young AdultABSTRACT
In cardiac surgery, supplementation with recombinant factor VIIa is the treatment of choice for patients with factor VII deficiency, but overzealous administration can be associated with thromboembolic side-effects. A 53-year-old man with factor VII activity 15.2%, international normalized ratio 2.9, and acute thrombotic critical coronary anatomy, underwent coronary artery bypass surgery and a thoracotomy with decortication 5 months later. He was managed successfully without recombinant factor VIIa supplementation. This case demonstrates that current bedside and laboratory tests such as thromboelastography, prothrombin time or international normalized ratio, and factor VII activity may not predict replacement therapy in these patients.
Subject(s)
Blood Coagulation/drug effects , Coronary Artery Bypass , Coronary Disease/surgery , Factor VII Deficiency/drug therapy , Factor VIIa/administration & dosage , Hemostatics/administration & dosage , Spondylitis, Ankylosing/surgery , Thoracotomy , Clinical Decision-Making , Coronary Artery Bypass/adverse effects , Coronary Disease/complications , Coronary Disease/diagnosis , Drug Administration Schedule , Drug Monitoring/methods , Factor VII Deficiency/blood , Factor VII Deficiency/complications , Factor VII Deficiency/diagnosis , Factor VIIa/adverse effects , Hemostatics/adverse effects , Humans , International Normalized Ratio , Male , Middle Aged , Patient Selection , Predictive Value of Tests , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Spondylitis, Ankylosing/complications , Spondylitis, Ankylosing/diagnosis , Thoracotomy/adverse effects , Thrombelastography , Treatment OutcomeABSTRACT
Organ transplant in patients with congenital bleeding disorders is a challenge requiring an integrated approach of various specialists. Inherited factor VII deficiency is the most common of the rare bleeding disorders, with a wide set of hemorrhagic features. Although a kidney allograft is the most frequent type of solid-organ transplant, it is rarely performed in individuals with congenital hemorrhagic disorders. Here, we highlight the course of a patient with coagulation factor VII deficiency who underwent successful kidney transplant without significant coagulopathy. Our patient was a 19-year-old man with end-stage kidney disease and congenital coagulation factor VII deficiency. Perioperative bleeding was successfully prevented by administration of recombinant factor VII, confirming its safety in solid-organ transplants. Success requires evaluation of doses and therapeutic schedules, as well as a multidisciplinary approach.
Subject(s)
Blood Loss, Surgical/prevention & control , Coagulants/administration & dosage , Factor VII Deficiency/drug therapy , Factor VIIa/administration & dosage , Kidney Failure, Chronic/therapy , Kidney Transplantation , Blood Coagulation/drug effects , Drug Monitoring/methods , Factor VII Deficiency/blood , Factor VII Deficiency/complications , Factor VII Deficiency/diagnosis , Graft Survival/drug effects , Humans , Immunosuppressive Agents/administration & dosage , International Normalized Ratio , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/diagnosis , Male , Recombinant Proteins/administration & dosage , Treatment Outcome , Young AdultABSTRACT
OBJECTIVE: Factor VII deficiency is the commonest of the rare bleeding disorders with limited knowledge on clinical profile. The objective of this study was to study the prevalence and clinico-hematological profile of factor VII-deficient patients. METHODS: It is a retrospective observational study of probable inherited factor VII deficiency covering 18 months. Their clinical profile, family history, investigation and treatment records were studied in detail. RESULTS: The study group comprised of total 12 factor VII deficiency cases with mean age of 17.5 years of onset of symptoms. The commonest symptom was menorrhagia (41.6%) followed by epistaxis (25%) and easy bruisability (16.6%). These 12 patients when categorized according to bleeding severity: severe bleeding - 2, moderate bleeding - 3, mild bleeding - 6 and asymptomatic - 1. All cases had prolonged prothrombin time (PT) with mean PT of 35.4âseconds (range 18-50âseconds) and mean prolongation of PT from upper limit of normal - 19.4âseconds (range 2-34âseconds). Factor VII levels ranged from < 1-40% in these patients. Clinical symptoms were not in concordance with factor levels. Of 12 patients, required treatment other than local measures. DISCUSSION AND CONCLUSION: Inherited factor VII deficiency is the commonest autosomally inherited factor deficiency with marked variation in the age of presentation and clinical symptoms. The laboratory results in form of PT and factor VII levels do not correlate with the severity of clinical presentation. A comprehensive evaluation to exclude acquired causes of factor VII deficiency, e.g. obesity, liver diseases, vitamin K deficiency and acquired inhibitors is required before labeling it as inherited in the absence of family history and molecular studies.
Subject(s)
Factor VII Deficiency/blood , Factor VIII/metabolism , Hemorrhage/blood , Adolescent , Adult , Aged , Child , Child, Preschool , Factor VII Deficiency/therapy , Female , Hemorrhage/therapy , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
Factor VII (FVII) serves an essential role in the initiation of blood coagulation. Mutations in conserved residues within its serine protease domain may lead to dysregulated coagulation activity. The objective of the present study was to elucidate the impact of altering two conserved residues, H348R and S282R, on the functional properties of the FVII protein. The mutationharboring fragments were derived from genomic DNA of a FVII deficient patient. The fragments were integrated into a pcDNA vector containing FVII cDNA of HepG2 cells. The wild-type and mutated FVII constructs were transfected into CHOK1 cells as a mammalian cell model. The coagulation activity, antigen levels and intracellular localization of the recombinant proteins were studied in association with their pathological importance. Results indicated that FVII activity was not detectable in conditioned media of the cells transfected with the mutated constructs. The H348R mutation reduced the expression of intracellular and secreted forms of the FVII protein. Following S282R transfection, intracellular FVII expression showed no significant variation; however, extracellular protein was reduced. The pattern of intracellular localization of mutated FVII remained unaltered in comparison to the wild-type protein. In conclusion, the present study suggested that missense mutations within the serine protease domain of FVII affect extracellular levels in addition to the coagulation activity of FVII. These results may contribute to further understanding of the molecular pathogenesis of FVII deficiency and the development of pharmaceutical candidates with improved therapeutic properties.
Subject(s)
Factor VII Deficiency/genetics , Factor VII/genetics , Gene Expression , Mutation , Amino Acid Substitution , Animals , CHO Cells , Cell Line , Cricetulus , Factor VII/metabolism , Factor VII Deficiency/blood , Factor VII Deficiency/metabolism , Genetic Association Studies , Humans , Immunohistochemistry , TransfectionABSTRACT
Factor VII (FVII) deficiency is one of the rare inherited bleeding disorders. Thrombosis has been occasionally described in inherited FVII deficiency. Here, we report a young female with undiagnosed FVII deficiency who presented with cerebral venous sinus thrombosis (CVST). Oral contraceptive pill was found to be prothrombotic risk factor. The CVSToccurred in spite of the congenital FVII deficiency indicating that no definitive antithrombotic protection is assured by this defect. Low molecular weight heparin and anti-Xa assay were found to be safe choice of anticoagulation and monitoring, respectively, in this patient.
Subject(s)
Blood Coagulation Factors/administration & dosage , Contraceptives, Oral/adverse effects , Factor VII Deficiency/complications , Heparin, Low-Molecular-Weight/administration & dosage , Sinus Thrombosis, Intracranial/chemically induced , Venous Thrombosis/chemically induced , Adult , Blood Coagulation Factors/therapeutic use , Brain/diagnostic imaging , Coagulants , Contraceptives, Oral/administration & dosage , Factor VII Deficiency/blood , Factor VII Deficiency/drug therapy , Female , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Sinus Thrombosis, Intracranial/complications , Sinus Thrombosis, Intracranial/drug therapy , Tomography, X-Ray Computed , Treatment Outcome , Venous Thrombosis/complications , Venous Thrombosis/drug therapyABSTRACT
Development of neutralising antibodies (inhibitors) against factor VIII (FVIII) is a frequent and severe complication of replacement therapy in haemophilia A. Previous data from haemophilia A mouse model demonstrates that both CD32 inhibition and high doses of rhFVIII prevent the differentiation of FVIII-specific memory B cells (MBCs) into antibody secreting cells (ASCs). Here, cellular targets responsible for the suppression of ASC formation by means of CD32 inhibition and high dose of rhFVIII were analysed. We investigated apoptosis on FVIII-specific MBCs using a pan caspases inhibitor, and screened for defects in rhFVIII presentation by analysing T cell release of Th1- and Th2-cytokines in vitro. Although high dose of rhFVIII suppressed ASC formation, cytokine response was not affected. Upon re-stimulation of splenocytes with high dose of rhFVIII, prevention of apoptosis fully restored the FVIII-specific recall response. In contrast, genetic deletion or inhibition of CD32 significantly altered Th1- and Th2-response. CD32 blockade and inhibition of apoptosis resulted in a partial rescue of FVIII-specific ASCs. Normal cytokine secretion could not be restored. In conclusion, suppression of FVIII-specific recall response by CD32 and high doses of rhFVIII is mediated by distinct mechanisms. High dose of rhFVIII induces apoptosis in FVIII-specific MBCs but does not influence FVIII-specific T cell response. CD32 blockade, however, may suppress the FVIII-specific recall response by two ways: i) increasing apoptosis of FVIII-specific MBCs and ii) disturbing FVIII-specific T cell response by modulating presentation of rhFVIII to CD4+ T cells in vitro.
Subject(s)
Antibodies, Neutralizing/immunology , B-Lymphocytes/immunology , Coagulants/administration & dosage , Factor VII Deficiency/drug therapy , Factor VIII/administration & dosage , Immunologic Memory , Receptors, IgG/metabolism , Animals , Antibodies, Monoclonal/pharmacology , Antibodies, Neutralizing/blood , Apoptosis , B-Lymphocytes/drug effects , B-Lymphocytes/metabolism , B-Lymphocytes/pathology , Cells, Cultured , Coagulants/immunology , Cytokines/immunology , Cytokines/metabolism , Disease Models, Animal , Factor VII Deficiency/blood , Factor VII Deficiency/genetics , Factor VII Deficiency/immunology , Factor VIII/genetics , Factor VIII/immunology , Genetic Predisposition to Disease , Immunologic Memory/drug effects , Mice, Knockout , Phenotype , Receptors, IgG/antagonists & inhibitors , Receptors, IgG/deficiency , Receptors, IgG/genetics , T-Lymphocytes, Helper-Inducer/immunology , T-Lymphocytes, Helper-Inducer/metabolism , Time FactorsABSTRACT
Congenital factor VII (FVII) deficiency is a rare bleeding disorder caused by mutations in F7 gene with autosomal recessive inheritance. A clinical heterogeneity with poor correlation with FVII:C levels has been described. It was the objective of this study to identify genetic defects and to evaluate their relationships with phenotype in a large cohort of patients with FVII:C<50 %. One hundred twenty-three probands were genotyped for F7 mutations and three polymorphic variants and classified according to recently published clinical scores. Forty out of 123 patients (33 %) were symptomatic (43 bleedings). A severe bleeding tendency was observed only in patients with FVII:C<0.10 %. Epistaxis (11 %) and menorrhagia (32 % of females in fertile age) were the most frequent bleedings. Molecular analysis detected 48 mutations, 20 not reported in the F7 international databases. Most mutations (62 %) were missense, large deletions were 6.2 %. Compound heterozygotes/homozygotes for mutations presented lower FVII:C levels compared to the other classes (Chi2=43.709, p<0,001). The polymorphisms distribution was significantly different among the three F7 genotypic groups (Chi2=72.289, p<0,001). The presence of truncating mutations was associated with lowest FVII:C levels (Chi2=21.351, p=0.002). This study confirms the clinical and molecular variability of the disease and the type of symptoms. It shows a good correlation between the type of F7 mutation and/or polymorphisms and FVII:C levels, without a direct link between FVII:C and bleeding tendency. The results suggest that large deletions are underestimated and that they represent a common mechanism of F7 gene inactivation which should always be investigated in the diagnostic testing for FVII deficiency.
Subject(s)
Factor VII Deficiency/blood , Factor VII Deficiency/genetics , Factor VII/genetics , Factor VII/metabolism , Hemostasis/genetics , Mutation , Polymorphism, Genetic , Adolescent , Adult , Aged , Aged, 80 and over , Blood Coagulation Tests , Child , Child, Preschool , DNA Mutational Analysis , Factor VII Deficiency/diagnosis , Female , Genetic Association Studies , Genetic Markers , Genetic Predisposition to Disease , Heterozygote , Homozygote , Humans , Italy , Male , Middle Aged , Phenotype , Young AdultABSTRACT
Severe congenital factor VII (FVII) deficiency is a rare bleeding disorder. Prophylaxis with replacement therapy has been suggested to patients, yet the most beneficial dosing regimens and therapy intervals are still to be defined. Due to the lack of evidence-based data, we hereby present our experience with long-term administration and monitoring primary prophylaxis in children with severe FVII deficiency and an extremely high bleeding risk. Four children with familial FVII deficiency, treated by prophylactic recombinant activated factor VII (rFVIIa), 15-30µg/kg/dose, given 2-3 times weekly since infancy, are discussed. Clinical follow up and monitoring laboratory assays, including thrombin generation, measured at various time points after prophylactic rFVIIa administration are presented. Among our treated patients neither FVII activity nor thrombin generation parameters (both already declined 24h post rFVIIa administration) were able to predict the impact of prophylaxis, and could not be used as surrogate markers in order to assess the most beneficial treatment frequency. However, the long clinical follow-up and comprehensive laboratory assessment performed, have shown that early primary prophylaxis as administered in our cohort was safe and effective.
Subject(s)
Factor VII Deficiency/prevention & control , Factor VIIa/therapeutic use , Child , Child, Preschool , Factor VII Deficiency/blood , Factor VII Deficiency/complications , Factor VII Deficiency/metabolism , Factor VIIa/administration & dosage , Female , Hemorrhage/blood , Hemorrhage/etiology , Hemorrhage/metabolism , Hemorrhage/prevention & control , Humans , Male , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Thrombin/metabolismABSTRACT
While the immune response to hemophilic factors in hemophilia has been widely studied, little is known about the development of anti-Factor VII (FVII) antibodies in FVII deficiency. We developed a robust technique based on the x-MAP technology to detect the presence of antibodies against FVII and characterize their isotype and validated this method using blood samples from 100 patients with FVII deficiency (median FVII clotting activity [FVII:C]: 6%) and 95 healthy controls. Anti-FVII antibodies were detected in patients but also in some controls, although the concentration of total immunoglobulin G (IgGt) and IgG1 and IgG4 subclasses was significantly different between groups. The IgG1 subclass concentrations remained significantly different also when only untreated patients were compared with controls. This difference could partially be related to the F7 genotype, particularly in patients harboring the p.Arg139Gln mutation. This x-MAP-based method might be useful for assessing the immunogenicity of novel FVII compounds and of activated FVII (FVIIa) concentrates. Further prospective studies are needed to better understand the clinical relevance of these antibodies in the management of patients with FVII deficiency.
Subject(s)
Antibodies, Neutralizing/immunology , Factor VII Deficiency/immunology , Factor VII Deficiency/therapy , Factor VII/immunology , Factor VIIa/immunology , Factor VIIa/therapeutic use , Immunoglobulin G/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Neutralizing/blood , Child , Child, Preschool , Cohort Studies , Factor VII Deficiency/blood , Female , Humans , Immunoassay/methods , Immunoglobulin G/blood , Infant , Male , Middle Aged , Recombinant Proteins/immunology , Recombinant Proteins/therapeutic use , Young AdultABSTRACT
BACKGROUND: To explore the characteristics of laboratory examination and confirm the diagnosis of a patient with combined inherited FVII and FX deficiency after he ingested diphacinone rodenticide accidentally. METHODS: The coagulant parameter screening tests and coagulation factor activities were tested many times in the patient due to accidental ingestion of a diphacinone rodenticide. After the patient was treated for more than one year, gene analysis of correlated coagulation factors was analyzed in the patient and other family members by DNA direct sequencing. 106 persons were selected as controls from routine health examinations. RESULTS: After the patient was admitted to hospital, routine coagulation screening tests revealed the prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT) and low levels of vitamin K-dependent coagulation factors (FII, FVII, FIX, FX) activity, which was 102.4 seconds, 88.5 seconds, 7%, 3%, 8%, and 2%, respectively. During more than one year of treatment, the value of PT and APTT still showed significantly prolonged activity and FVII and FX activity levels were about 5%. While FII and FIX activity levels were in the normal range after 12 weeks of treatment. Two homozygous mutations, g.11267C>T of F7 gene resulting in the substitution Arg277Cys and g.28139G>T of F10 gene leading to the substitution Val384Phe, were identified in the patient. The patient's parents and sister was heterozygous for Arg277Cys and Val384Phe mutations. FVII and FX antigen levels in the patient were 7% and 30%, respectively. CONCLUSIONS: There were many similarities in the characteristics of laboratory examination between combined inherited FVII and FX deficiency and acquired vitamin K deficiency. The best way to identify them was gene analysis.